期刊
BLOOD
卷 137, 期 21, 页码 2935-2946出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020008311
关键词
-
类别
资金
- la Caixa Foundation [LCF/PR/HR17/52150017, HR17-00221]
- European Research Council under the EU Horizon 2020 research and innovation program [810287]
- Instituto de Salud Carlos III
- European Regional Development Fund Una manera de hacer Europa [PMP15/00007]
- CERCA Programme/Generalitat de Catalunya
- Ministerio de Ciencia e Innovacion [BES2016-076372]
- Generalitat de Catalunya Suport Grups de Recerca AGAUR [2017-SGR-1142]
The B-cell receptor (BCR) signaling is crucial for chronic lymphocytic leukemia (CLL) biology, with IGLV3-21-expressing B cells potentially acquiring a single point mutation (R110) triggering autonomous BCR signaling. Epigenetic studies have identified 3 CLL subtypes, with IGLV3-21(R110) CLL defining a subgroup with specific biological features and an unfavorable prognosis independent of IGHV mutational status and epigenetic subtype.
B-cell receptor (BCR) signaling is crucial for chronic lymphocytic leukemia (CLL) biology. IGLV3-21-expressing B cells may acquire a single point mutation (R110) that triggers autonomous BCR signaling, conferring aggressive behavior. Epigenetic studies have defined 3 CLL subtypes based on methylation signatures reminiscent of naive-like (n-CLL), intermediate (i-CLL), and memory-like (m-CLL) B cells with different biological features. i-CLL carries a borderline IGHV mutational load and significantly higher use of IGHV3-21/IGLV3-21. To determine the clinical and biological features of IGLV3-21(R110) CLL and its relationship to these epigenetic subtypes, we characterized the immunoglobulin gene of 584 CLL cases using whole-genome/exome and RNA sequencing. IGLV3-21(R110) was detected in 6.5% of cases: 30 (38%) of 79 i-CLLs, 5 (1.7%) of 291 m-CLLs, and 1 (0.5%) of 189 n-CLLs. All stereotype subset 2 cases carried IGLV3-21(R110), whereas 62% of IGLV3-21(R110) i-CLL cases had nonstereotyped BCR immunoglobulins. IGLV3-21(R110) i-CLL had a significantly higher number of SF3B1 and ATM mutations and total number of driver alterations. However, the R110 mutation was the sole alteration in 1 i-CLL and was accompanied only by del(13q) in 3. Although IGHV mutational status varied, IGLV3-21(R110) i-CLL transcriptomically resembled n-CLL/unmutated IGHV CLL with a specific signature including WNT5A/B overexpression. In contrast, i-CLL lacking IGLV3-21(R110) mirrored m-CLL/mutated IGHV. Patients with IGLV3-21(R110) i-CLL had a short time to first treatment and overall survival similar to those of n-CLL/unmutated IGHV patients, whereas patients with non-IGLV3-21(R110) i-CLL had a good prognosis similar to that of patients with m-CLL/mutated IGHV. IGLV3-21(R110) defines a CLL subgroup with specific biological features and an unfavorable prognosis independent of IGHV mutational status and epigenetic subtype.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据